Search

Jean Bernard Lifetime Achievement Award

The Jean Bernard Lifetime Achievement Award was established in 2008 to honor outstanding physicians and scientists for their lifetime contribution to the advancement of hematology.

Read more

EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease

November 10-11, 2022 | Bordeaux, France

Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.

Read more

Harnessing new developments in genomics to improve outcome for children with poor prognosis leukemia

At the 19th Congress of the European Hematology Association (EHA), we will learn about the state-of-the-art in management of childhood AML.

Read more

SWG Educational Activities

EHA-SWG SCIENTIFIC MEETING ON INTEGRATED CELL TRACKING IN ONCOHEMATOLOGY: DIAGNOSIS, TARGETED THERAPY AND RESIDUAL DISEASE

November 10-11, 2022 | Bordeaux, France

Meeting Chairs:

MC Béné, Nantes University

G Zini, Università Cattolica S.

Read more

Hospital pharmacists and regulators lead the way on shortages

EHA welcomes initiatives but calls for more focus on causes

Medicine shortages have a negative impact on the quality and cost of treatments and on patient access to the best possible care.

Read more

Strengthening Resilience and Fostering Collaboration: Ensuring a Transparent and Reliable Supply Chain for Plasma-Derived Products

The issue of immunoglobulin shortages and the importance of enhancing and maintaining plasma supplies have gained significant attention within the policy and regulatory landscape of the European Union.

Read more

Mini-hormone fights iron

Iron overload commonly leads to organ damage and even death. Currently available treatments for iron overload are burdensome or cause side effects.

Read more

Expert opinions for COVID-19 vaccination in patients with hematologic cancer

Ronja Brockhoff, Hamdi Akan, Rafael Duarte, Martin Hönigl, Nikolay Klimko, Sibylle C. Mellinghoff, Livio Pagano, Antonio Pagliuca, Paul Verweij, Oliver A.

Read more

EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation

To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more